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platinum and mitomycin C (22) . Recently, JNK has been implicated in the regulation of apoptosis (23; 24) . However, the mechanism(s) and functional role for JNK in the regulation of apoptosis are not clear (24) . On the one hand, reports suggest that activation of JNK can be associated with induction of apoptosis. For example, it was found that nerve growth factor withdrawal from post-mitotic rat PC12 pheochromocytoma cells resulted in JNK activation in association with apoptosis (18, 25) . JNK is also activated following other stress applications including irradiation, TNFα, or Fas-ligand treatment (FasL; 26, 27) . In addition, in both sympathetic neurons and PC12 cells, expression of a dominant-negative mutant of c-Jun, or microinjection of c-Jun neutralizing antibodies, are able to inhibit apoptosis (28, 29) . These data also suggest that phosphorylation of c-Jun by JNK is closely associated with apoptosis.
However, these studies did not indicate a potential mechanism by which JNK activation and/or c-Jun phosphorylation might trigger apoptosis. Interestingly, it has recently been proposed that the JNK/c-Jun/FasL signaling pathway may play a role in induction of neuronal cell death in response to various stresses via up-regulation of FasL expression (18) . On the other hand, evidence has been reported that JNK activation is involved in cell survival. Epidermal growth factor (EGF) or phorbol ester (TPA) treatment of cells induces activation of JNK in association with cell survival (23) . Lymphocytes deficient in upstream activation of JNK by JNKK1/SEK1 are reported to be more sensitive to Fasmediated apoptosis (30) , suggesting that JNK activation is required for prolonged cell survival following a stress event. In support of this notion, lymphocytes from TRAF2 -/ -mice, which are defective in JNK activation, are highly sensitive to TNF-induced apoptosis (31) . Even stronger evidence in favor of this hypothesis derives from the analysis of compound mutant JNK1 -/ -JNK2 -/ -embryos that exhibit increased apoptosis 6 murine FDC-P1 cells expressing high levels of endogenous Bcl2 were maintained as previously described (8) . Flag-tagged DN-JNK1/ pcDNA3 was transfected into FDC-P1 cells by electroporation. Clones stably expressing Flag-epitope-tagged DN-JNK1 were selected in medium containing G418 (0.6mg/ml).
Metabolic labeling, immunoprecipitation, and Western blot analysis.
Cells were washed with phosphate-free RPMI medium and incubated with 32 Porthophosphoric acid for 60 min or for an indicated time as previously described (12) .
After agonist or inhibitor addition for the indicated times, cells were washed with icecold PBS, lysed in detergent buffer, and Bcl2 was immunoprecipitated from the lysates as described previously (12) . The samples were subjected to 10-20% gradient SDS/PAGE, transferred to a nitrocellulose membrane and exposed to Kodak X-Omat film at -80 o C for the times indicated. The filters were probed by Western blot analysis with a Bcl2 antibody and developed by using an ECL kit (Amersham) as described previously (12) .
Assay of JNK activity and Bcl2 phosphorylation in Vitro.
JNK1 was immunoprecipitated from cell lysates with polyclonal JNK1 antibody following IL-3 withdrawal or agonist treatment. GST-c-Jun (1ug) was used as substrate and was added to 30ul of kinase assay buffer (25mM HEPES, pH7. sample for 5 min. The samples were analyzed by SDS/PAGE as previously described (12) . Subcellular Fractionation. Subcellular fractionation was performed to isolate heavy membrane (HM), light membrane (LM), cytosol (Cyto), and nuclear membrane (Nuc) as described previously (13, 14, 35) . Total protein (50ug) from each fraction was subjected to SDS/PAGE and analyzed by Western blotting using antibodies to Bcl2 and JNK1. The purity of fractions was confirmed by assessing localization of faction-specific proteins including prohibitin (HM) and CPP32 (cytosolic ) as previously described (14) .
Cell viability assay. The apoptotic and viable cells were detected by using ApoAlert 
Results
WT but not S70A Bcl2 prolongs cell survival following stress treatments including IL-3 withdrawal and low dose okadaic acid. Bcl2 is an integral intracellular membrane protein that inhibits programmed cell death induced by multiple insults in a wide variety of cell types (36) . IL-3 induces cell survival and Bcl2 phosphorylation at ser70 through both PKC-dependent (8, 13) and PKC-independent (i.e.ERK1/2) pathways (14) . To test whether phosphorylation of Bc12 at ser70 is also required for prolonged cell survival okadaic acid in the absence of growth factor as described in "Methods". Annexin-V binding to phophatidylserine that has translocated to the outer plasma membrane is a reliable early marker of apoptosis (37) . Importantly, Bcl2 protein levels were similar in both WT and S70A Bcl2 transfectants (Fig.1A) . Results indicated that survival is Fig.2A, 9 B). JNK1 activity was assessed using its physiologic substrate c-Jun as described in "Methods". Since JNK2 is not detected in these cells (data not shown), its role was not further studied. ERK1/2 and p38 kinase activation were also assessed by Western blot analysis using a phospho-specific ERK or p38 antibody respectively that recognizes the activated forms of these two MAPKs. Interestingly, both the ERK1/2 and p38 kinase activities are substantially reduced by 6-12h following IL-3 withdrawal, a time by which JNK1 activity is increased 1.5 -3.2 fold (Fig 2) . These findings suggest a differential activation mechanism for JNK-1 following stress and indicate that JNK1, but not ERKs1/2 or p38 kinases, is a potential SAK. 
JNK1 co-localizes with Bcl2 in mitochondrial membranes and directly phosphorylates Bcl2 in vitro.
Bcl2 is thought to function in survival signaling in mitochondrial membrane (5, 40) . To assess a role for JNK1 as a Bcl2 kinase, subcellular fractionation experiment was performed as described (14) . Results reveal that Bcl2 colocalizes with JNK1 in mitochondrial membranes, as recently reported ( Since the ser70 site of Bcl2 is a putative proline-directed phosphorylation site that is known to be a target of ERKs1/2 (14), ser70 may also be the substrate for other MAPKs.
To test whether the MAPK/JNK1 can directly phosphorylate Bcl2 at ser70, we established an in vitro reconstitution kinase assay as described in "Methods". The findings indicate that while anisomycin treatment of cells does not prolong survival in the absence of IL-3 (Fig. 6D) , anisomycin also does not significantly increase the rate of cell death under these conditions (Fig. 6D) , even though anisomycin is reported to be toxic to cells by inhibiting protein synthesis (39) . This may potentially be explained since anisomycin provides a potential survival signal by activating JNK1 and resulting in Bcl2 phosphorylation (Fig. 6C) Thus, DN-JNK1 not only can block stress-induced Bcl2 phosphorylation but can also promote a more rapid cell death following such applications (Fig. 6D) . These data strongly suggest that the functional role of JNK1 as a SAK is to prolong cell survival following stress which, under some circumstances, may represent only an agonal attempt to maintain the antiapoptotic function of Bc12.
Interestingly, our findings indicate that JNK1 is not only latently activated following IL-3 withdrawal but also can be rapidly activated following the addition of the survival agonists IL-3 or Bryo. These findings support the notion that JNK1 may play a dual role in both IL-3 mediated survival and stress-activated signaling relative to cell survival (Fig.   8 ). The dynamics of IL-3-induced JNK1 activation and Bcl2 phosphorylation is rapid (15-30 min) and reversible ( Fig. 8; 35 ), while that for activation of JNK1 and Bcl2 phosphorylation is latent, being observed only between 6-12h following IL-3 withdrawal ( Fig.2A, B) . Any differential mechanism(s) for early vs latent activation of JNK1 are not yet clear, and further studies will be required. The rapid activation of JNK1 may result from PKC activation that occurs following IL-3 addition to cells because bryostatin-1, a potent PKC activator and survival stimulator in factor dependent cells (8) , can also rapidly activate cellular JNK1 (Fig.8) . On the other hand, latent activation of JNK1, which may account for prolonged cell survival following stress, does not appear to involve PKC or other MAPKs, including the ERKs or p38 kinase (Fig. 2) . Presently, how JNK1 is latently activated remains to be determined. Interestingly, only the WT, Inactivation by paclitaxel is thought to occur when Bcl2 is phosphorylated at two other residues (Thr69 and Ser87) in addition to Ser70 (i.e. multiple-site phosphorylation) (20) .
Therefore, it is possible that multiple-site phosphorylation may differ functionally from ser70 mono-site phosphorylation to regulate Bcl2's antiapoptotic function, perhaps by inducing an additional conformational change. While Further work will be required to explain the mechanism, it should be noted that paclitaxel can also act directly on mitochondria isolated from human cancer cells to mediate the release of cytochrome C and activate caspases that initiate apoptosis in a mechanism apparently independent of Bcl2 (52). Thus the role of multi-site Bcl2 phosphorylation in paclitaxel-induced death is mechanistically unclear.
Our findings indicate that JNK1-induced phosphorylation of Bcl2 may be required to facilitate prolonged survival following stress conditions that ultimately lead to cell death if not reversed. The mechanism(s) by which phosphorylation can enhance Bcl2's function
is not yet clear but, at least in part, phosphorylation appears to maintain a stable association between Bcl2 and its proapoptotic partner, Bax (14) . In addition, phosphorylation of Bcl2 has been recently reported to prevent degradation and thereby anisomycin (10ug/ml) for various times as indicated. JNK1 activity was analyzed as described in Fig. 2A. (B) H7 cells expressing WT or S70A mutant Bcl2 were metabolically labeled with 32 P-orthophosphoric acid for 1h and treated with anisomycin (10ug/ml) for 30'. Bcl2 phosphorylation was determined as described in Fig. 2B . were treated with IL-3 (1ug/ml) or Bryo (100nM) for various times as the indicated.
JNK1 activity was analyzed as described in Fig by guest on September 1, 2017
